Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12

Benzinga · 23h ago
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.